The look of future Id vaccine trials should incorporate such T cell assays to improve sensitivity also to identify relevant immunologic correlates of tumor regression or improved survival
The look of future Id vaccine trials should incorporate such T cell assays to improve sensitivity also to identify relevant immunologic correlates of tumor regression or improved survival. After a median follow-up greater than 6 years (77 months), 43% of our patients stay in continuous first complete remission (CR or CRu) for periods which range…